About Owkin
                            Owkin is an AI precision medicine company with a vision to find the right drug for every patient.                        
                                                    
                                    Headquarters
                                    Owkin, New York
                                
                                                                                                
                                    Founded
                                    2016-01-01
                                
                                                                
                                                                
                                    Industry
                                    Artificial Intelligence (AI), Biotechnology, Clinical Trials, Machine Learning, Pharmaceutical, Precision Medicine
                                
                                                                                                
                                    Last Funding Type
                                    Series B
                                
                                                                                                    
                                        Valuation
                                        3
                                    
                                                                                                
                                                                        Total Funding
                                    $304.10 million dollars
                                
                                                                                                
                                    IPO Status
                                    Private
                                
                                                            Financial
                                Owkin is advancing AI precision medicine through various research areas. They are developing systems for image classification and preprocessing, which involve segmenting images into regions of interest using convolutional neural networks. Their work includes detecting tertiary lymphoid structures in histology images and predicting breast cancer prognosis by analyzing whole slide images. Additionally, Owkin is focused on identifying features of pancreatic ductal adenocarcinoma from histopathology slides. These efforts highlight their commitment to enhancing diagnostic and prognostic capabilities in medicine.
                            
                            
                                    Funding Rounds
                                    8
                                
                                                                                                
                                    Number of Lead Investors
                                    8
                                
                                                                                                
                                                                        Total Funding Amount 
                                    $304.10 million dollars
                                
                                                                                                
                                    Number of Investors
                                    16